Skip to main content
Cohance Lifesciences Limited (BOM:543064)
India flag India · Delayed Price · Currency is INR
494.15
+61.45 (14.20%)
At close: Apr 28, 2026

Cohance Lifesciences Revenue

Cohance Lifesciences had revenue of 5.45B INR in the quarter ending December 31, 2025, with 77.29% growth. This brings the company's revenue in the last twelve months to 10.79B, up 2.90% year-over-year. In the fiscal year ending March 31, 2025, Cohance Lifesciences had annual revenue of 11.98B with 13.91% growth.

Revenue (ttm)
10.79B
Revenue Growth
+2.90%
P/S Ratio
17.49
Revenue / Employee
8.90M
Employees
1,212
Market Cap
188.72B

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Mar 31, 202511.98B1.46B13.91%
Mar 31, 202410.51B-2.89B-21.56%
Mar 31, 202313.40B201.07M1.52%
Mar 31, 202213.20B3.11B30.75%
Mar 31, 202110.10B1.76B21.10%
Mar 31, 2020 Pro Pro Pro
Mar 31, 2019 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Caplin Point Laboratories 20.92B
Jubilant Pharmova 79.18B
Rubicon Research 15.98B
Granules India 50.92B
CORONA Remedies 13.44B
Viyash Scientific 18.17B
AstraZeneca Pharma India 21.77B
Procter & Gamble Health 13.49B
Revenue Rankings

Cohance Lifesciences News

More News